Navaux, Inc. is building upon proprietary technology to provide cancer patients and their physicians with direction beyond diagnostics. Through our pipeline of novel proteins we are not only able to detect cancer in it earliest form but we are using this same technology to aid in treatment monitoring and ultimately targeted drug delivery. We understand the "cancer cascade" that occurs when cells seemingly experience uncontrolled growth. By developing non-invasive blood tests to measure proteins that are both capable and active in cancer progression, we can identify, target and potentially deliver therapies to the tumors at their earliest stage.